Stifel Nicolaus lowered shares of Avanos Medical (NYSE:AVNS) from a buy rating to a hold rating in a research note published on Wednesday, AnalystRatings.com reports. Stifel Nicolaus currently has $35.00 price target on the stock, down from their previous price target of $45.00.
A number of other equities research analysts have also recently issued reports on AVNS. Zacks Investment Research upgraded Avanos Medical from a sell rating to a hold rating and set a $46.00 price objective for the company in a report on Wednesday, October 30th. Raymond James downgraded shares of Avanos Medical from an outperform rating to a market perform rating in a research report on Wednesday. ValuEngine downgraded shares of Avanos Medical from a strong-buy rating to a buy rating in a research report on Tuesday, November 5th. Finally, JMP Securities restated a hold rating on shares of Avanos Medical in a research report on Wednesday, August 21st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $44.80.
Shares of NYSE AVNS traded up $1.61 during mid-day trading on Wednesday, hitting $35.54. The company had a trading volume of 433,684 shares, compared to its average volume of 336,622. The company has a market capitalization of $1.77 billion, a PE ratio of 43.34 and a beta of 1.56. The firm has a 50-day simple moving average of $39.33 and a two-hundred day simple moving average of $39.95. The company has a current ratio of 3.06, a quick ratio of 2.35 and a debt-to-equity ratio of 0.25. Avanos Medical has a one year low of $31.78 and a one year high of $53.45.
Several large investors have recently modified their holdings of AVNS. BlackRock Inc. grew its holdings in shares of Avanos Medical by 0.4% in the 2nd quarter. BlackRock Inc. now owns 5,465,732 shares of the company’s stock worth $238,360,000 after acquiring an additional 23,000 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Avanos Medical by 4.3% in the second quarter. Victory Capital Management Inc. now owns 2,291,582 shares of the company’s stock worth $99,936,000 after purchasing an additional 94,857 shares during the period. Paradice Investment Management LLC increased its stake in shares of Avanos Medical by 12.9% in the third quarter. Paradice Investment Management LLC now owns 2,248,108 shares of the company’s stock worth $84,214,000 after purchasing an additional 256,525 shares during the period. Invesco Ltd. increased its stake in shares of Avanos Medical by 21.0% in the second quarter. Invesco Ltd. now owns 1,637,165 shares of the company’s stock worth $71,396,000 after purchasing an additional 284,234 shares during the period. Finally, Northern Trust Corp increased its stake in Avanos Medical by 6.7% during the second quarter. Northern Trust Corp now owns 1,371,355 shares of the company’s stock valued at $59,805,000 after acquiring an additional 85,694 shares during the period. Institutional investors and hedge funds own 94.14% of the company’s stock.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Read More: What is Green Investing?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.